is likely to be in focus as its competitor in Enbrel (Etanercept) biosimilar, Sandoz, is likely to see a delayed launch. While Sandoz has already received a USFDA approval for Etanercept biosimilar (Erelzi) in August-2016, a patent row is already going on between Enbrel’s innovator Amgen and biosimilar aspirant Sandoz. The patent trial was first set to take place in 2017 and then in April-2018; it has been further delayed. The trial will now start on June 20, 2018 delaying the first Enbrel biosimilar.
Sandoz had expected to launch Enbrel biosimilar in 2018; however, with the delay in the patent trial, Erelzi launch is now expected to take place in 2019, which will be positive for Biocon.
Enbrel recorded global sales of $8.9bn of which ~$5bn came from the US market in 2017. Any delay in the competition is positive for Biocon/Mylan who are currently conducting clinical trials on Enbrel biosimilar.